NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be exhibiting at the Annual Meeting of the American College...
Tailwinds' Take: "Less blood draws, quicker results". This research further positions the BVA-100 as a must have for hospitals. The big catalyst here? We expect to start seeing these clinical results translate into sales in the near future. When...
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data from Duke University Medical Center that was presented Saturday,...
NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital in Wausau Wisconsin has acquired a BVA-100...

Daxor Emerges

Accurate blood volume monitoring can save lives and reduce medical costs The BVA 100 is the only approved product on the market Hospitals are incentivized to adopt the product The market opportunity is large Daxor emerges Similar to how...
Daxor Corporation  February 28, 2019 Dear Fellow Shareholder: Daxor Corporation (“Daxor”or the “Company”) is an investment company with medical instrumentation and biotechnology operations. We have attached a report of our portfolio holdings and investment activity for the year ended December 31, 2018....
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces a new research initiative with a leading hospital in the Southeast using...
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the acquisition of Daxor's BVA-100 blood volume analyzer as part of standard...
Tailwinds' Take: we eventually expect to see a sharp uptick in growth from this already strong rate as the implications of the pivotal trial generate increased interest from the medical community. That likely starts to show itself this summer. NEW...
Tailwinds' Take: this is very positive for Daxor. If momentum starts to accelerate, DXR could be a great stock. We'd like to know if this is a one off event, or if the spigot is opening on a slew...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.